BRAINTREE, Mass., Aug. 9 /PRNewswire-FirstCall/ -- Haemonetics Corporation announced today it has signed a multi-year agreement with the American Red Cross to continue the use of Haemonetics’ red cell collection technology at Red Cross blood services regions in the U.S.
Under the agreement, the American Red Cross will continue to use Haemonetics’ red cell collection technology for double red cell collections. In a double red cell collection, a qualified blood donor can donate two units of red cells in one donation thereby helping to alleviate blood shortages.
The American Red Cross first implemented Haemonetics’ automated red cell collection technology into its operations in 2000 and since then has expanded use of the technology into 21 regions of its 35 regions.
The Red Cross will begin a trial of Haemonetics’ automated platelet collection technology in the near future.
John Grande, Vice President of Haemonetics’ Donor Division for North America, said, “Automated red cell collections have become mainstream in the U.S. blood collection industry as blood collectors leverage Haemonetics’ MCS(R) system to ensure enough blood is available for patients. We’re pleased that the American Red Cross will continue to use our red cell technology.”
Haemonetics is a global company engaged in the design, manufacture and worldwide marketing of automated blood processing systems. These systems address important medical markets: surgical blood salvage, blood component collection, plasma collection, and blood component safety. To learn more about Haemonetics’ products and markets, visit its web site at http://www.haemonetics.com.
This release contains forward looking statements that involve risks and uncertainties, including technological advances in the medical field and standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, product demand, market acceptance, regulatory uncertainties, the effect of economic and political conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, foreign currency exchange rates, changes in customers’ ordering patterns, the effect of industry consolidation as seen in the plasma market, the effect of communicable diseases and the effect of uncertainties in markets outside the U.S. (including Europe and Asia) in which we operate and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The foregoing list should not be construed as exhaustive. The forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results and experience could differ materially from the forward-looking statements.
CONTACT: Julie Fallon Tel. (781) 356-9517 Alternate Tel. (617) 320-2401 fallon@haemonetics.com
Haemonetics Corporation
CONTACT: Julie Fallon of Haemonetics Corporation, +1-781-356-9517 or+1-617-320-2401, fallon@haemonetics.com
Web site: http://www.haemonetics.com/
